A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Status:
Completed
Trial end date:
2019-07-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug known as
ramucirumab in children with recurrent or refractory solid tumors including central nervous
system (CNS) tumors.